

The 3rd International Conference on YWBCH -Young Women's Breast Cancer and Health-

Date

November 15(Sun), 2026

Time

12:15 ~ 13:15

Venue

Room2,

Omura Susumu & Mieko Memorial
St. Luke's Center for Clinical Academia

Metastatic Breast Cancers in Young Women ~What Makes It Unique and How Should We Treat It ?~

Chair

Tomoyuki Aruga

Professor, Department of Surgical Specialities,
Division of Breast Surgery, Institute of Science Tokyo

Speaker

Tetsuhiro Yoshinami

Center for Cancer Genomics and Personalized Medicine/
Department of Breast and Endocrine Surgery,
The University of Osaka Hospital

Indications

OUnresectable or recurrent hormone receptor-negative and HER2-negative breast cancer treated with prior chemotherapy.

OUnresectable or recurrent hormone receptor-positive and HER2-negative breast cancer treated with prior chemotherapy.

Co-sponsored by: The 3rd International Conference on YWBCH/
Gilead Sciences K.K.

YWBC2026 Luncheon Seminar 3

Sponsored by Gilead Sciences

Metastatic Breast Cancers in Young Women
~What Makes It Unique and How Should We Treat It ?~

Chair : Tomoyuki Aruga

Professor, Department of Surgical Specialities,
Division of Breast Surgery, Institute of Science Tokyo

Speaker : Tetsuhiro Yoshinami

Center for Cancer Genomics and Personalized Medicine/
Department of Breast and Endocrine Surgery,
The University of Osaka Hospital

【Overview and highlights of the seminar】

Metastatic breast cancer in young women (mYWBC) have distinct clinical, biological, and genomic characteristics. This seminar will review these unique features and discuss current treatment strategy and unmet needs. Sacituzumab Govitecan* is one of the standard treatments in HER2-negative metastatic breast cancer. This seminar will also address its use in mYWBC.

***INDICATIONS**

- Unresectable or recurrent hormone receptor-negative and HER2-negative breast cancer treated with prior chemotherapy.
- Unresectable or recurrent hormone receptor-positive and HER2-negative breast cancer treated with prior chemotherapy.